Kalobios Pharmaceuticals, Inc.
Records under this name other than patents Kalobios Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Kalobios Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,168,183 | Antibodies to granulocyte-macrophage colony-stimulating factor Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,017,674 | Antibodies to Granulocyte-Macrophage Colony-Stimulating Factor Formerly held In force · Low confidence | In force | Low confidence | |
| US 8,642,035 | Anti-Trkb Antibodies Formerly held In force · High confidence | In force | High confidence | |
| US 9,290,571 | Antibodies to EphA3 Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,834,870 | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3 Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,045,539 | Anti-EMR1 antibodies Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,109,032 | Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,664,365 | Antibodies to EphA3 Formerly held Lapsed on the fee record Ended Mar 4, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 4, 2026 | USPTO record |
| US 8,637,016 | EphA3 Antibodies for the Treatment of Solid Tumors Formerly held Lapsed on the fee record Ended Jan 28, 2026 · High confidence | Lapsed on the fee record | Ended Jan 28, 2026 | High confidence |
| US 7,981,843 | Antibody specificity transfer using minimal essential binding determinants Formerly held Lapsed on the fee record Ended Jul 19, 2023 · USPTO record | Lapsed on the fee record | Ended Jul 19, 2023 | USPTO record |